Am J Transplant, Volume 16, Suppl 3 Archives - Page 23 of 180 - ATC Abstracts

2016 American Transplant Congress
Assessing the Impact of the Share35 Liver Allocation Policy: Survival Outcomes Among Liver Re-Transplant Recipients.
J. Ortiz,¹ N. Koizumi,² C. Kwon,² Y. Zhang,² C. Ortiz.³
¹Department of Surgery, University of Toledo, Toledo, OH; ²George Mason University, Fairfax, VA; ³Bucknell University, Lewisburg, PA.
Liver retransplantation (reLTx) is the only treatment option for those who experienced graft loss after primary liver transplantation (LTx). Yet, in an era of increasing…
2016 American Transplant Congress
Immune Response to BK Virus in Renal Transplant Recipients.
D. DeWolfe,¹ J. Gandhi,¹ M. Mackenzie,¹ T. Broge,¹ E. Bord,¹ D. Mandelbrot,¹ R. Viscidi,² F. Cardarelli,¹ M. Pavlakis,¹ C. Tan.¹
¹Medicine, Beth Israel Deaconess Medical Center, Boston, MA; ²Pediatrics, Johns Hopkins Medical Center, Baltimore, MD.
Background: The adaptive immune characteristics associated with BK Virus (BKV) infection and control remain incompletely described. In this study we further elucidate the immune response…
2016 American Transplant Congress
AT1R Antibodies at 1-Year Negatively Impact 5-Year Native Renal Function in Liver Transplant Recipients.
J. O'Leary,¹ A. Philippe,² H. Heidecke,² R. Freeman,¹ L. Jennings,¹ R. Catar,² G. Klintmalm,¹ D. Dragun.²
¹Baylor Simmons Transplant Insttute, Baylor University Medical Center, Dallas, TX; ²Internal Medicine, Charite, Berlin, Germany.
Angiotensin II Type-1 Receptor (AT1R) antibodies have been associated with pulmonary hypertension, renal allograft loss, and fibrosis progression in liver allograft recipients especially if combined…
2016 American Transplant Congress
Role of Cardiac Evaluation and Management in Kidney and Liver Transplant Candidates.
W. Bannister, C. Wu, M. Schnitzler, A. Bonagura, B. Laihinen, F. Irwin.
Complex Medical Conditions, Optum, UnitedHealth Group, Eden Prairie, MN; Surgery, St Louis University, St Louis, MO.
Cardiac evaluation and risk stratification prior to kidney and liver transplantation can be critical to patient selection and outcomes.Methods: We assessed the impact of cardiac…
2016 American Transplant Congress
Evolution of Body Composition and Associations to Glucose Metabolism During the First Year After Kidney Transplantation.
M. von Düring,¹ A. Hartmann,^1,2 J. Bollerslev,^2,4 A. Åsberg,^1,3 K. Godang,⁴ I. Eide,¹ D. Dahle,¹ T. Jenssen.^1,5
¹Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ³School of Pharmacy, University of Oslo, Oslo, Norway; ⁴Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ⁵Metabolic and Renal Research Group, University of Tromsø, Tromsø, Norway.
Background. The evolution and association between body composition and glucose haemostasis after kidney transplantation has not been elucidated.Methods. We investigated 150 consecutive patients without suspected…
2016 American Transplant Congress
Hepatocellular Carcinoma Decreases Chance of Successful HCV Therapy in the Current Era.
S. Prenner, L. VanWagner, L. Kulik.
Gastroenterology and Hepatology, Northwestern University, Chicago, IL.
Background: The efficacy of direct acting antiviral agents (DAA) for hepatitis C (HCV) in patients with hepatocellular carcinoma (HCC) is limited. We hypothesized that virology…
2016 American Transplant Congress
RNAseq Transcriptome Analysis of Bone Marrow CD138⁺ Plasma Cell Responses to Carfilzomib Monotherapy Desensitization.
J. Driscoll, B. Aronow, S. Tremblay, R. Alloway, E. Woodle.
Medicine, Surgery, Biomedical Informatics, U of Cincinnati, Cincinnati Children's, Cincinnati, OH.
Purpose: Prior studies indicate that bone marrow resident plasma cells (BMRPCs) demonstrate varying sensitivity to proteasome inhibition (PI). Effects of carfilzomib (CFZ) monotherapy desensitization on…
2016 American Transplant Congress
Activated Cytoprotective Mechanisms in DBD Kidneys Correlate with Kidney Function in Transplant Recipients: A Study Using Clinical Samples from the UK QUOD Biobank.
M. Kaisar,¹ L. van Dullemen,² Z. Akhtar,¹ M. Lo Faro,¹ H. Huang,¹ H. Leuvenink,² B. Kessler,¹ R. Ploeg.¹
¹Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom; ²UMCG, UMCG, Groningen, Netherlands.
The onset of abnormal pathophysiological changes following brain death adversely impact kidney function following transplantation. Understanding the biological mechanisms that affect kidney quality will allow…
2016 American Transplant Congress
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.
H. Hirsch,¹ J. De Fijter,¹ M. van der Giet,¹ M. Zeier,¹ J. Pascual,¹ Y. Avihingsanon,¹ P. Lopez,² J. Aguilar-Sanchez,² J. Kochuparampil,² Z. Wang,³ H. Holdaas,¹ J. Cruzado.¹
¹ELEVATE Study Group, Basel, Switzerland; ²Novartis, Basel, Switzerland; ³Novartis Pharmaceutical Corporation, East Hanover.
BackgroundCytomegalovirus (CMV) and BK polyomavirus (BKPyV) infections are independent risk factors for acute rejection and graft loss. Early conversion from calcineurin inhibitors (CNIs) to everolimus…
2016 American Transplant Congress
Assessing Return of CMV Specific Cellular Immunity Using the T-SPOT.CMV Soon After Kidney Transplant with Thymoglobulin.
C. Kotton.
Infectious Disease, Massachusetts General Hospital, Boston, MA.
Background: We do not currently have sufficient predictive tools to determine risk of CMV infection after organ transplantation. Recent data suggest that assays of the…